Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anxiolytic Drugs: Overview

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

Anxiolytic Drugs: Benzodiazepines and Buspirone

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment.

Neurology and therapy·2025

Same author

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial.

CNS drugs·2025

Same author

Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.

CNS drugs·2025

Same author

The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorder.

European archives of psychiatry and clinical neuroscience·2025

Same author

Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials.

EClinicalMedicine·2025

Same author

Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission.

The lancet. Psychiatry·2025

Search research articles

Related Experiment Videos

Second-generation antipsychotics for anxiety disorders.

Anna M Depping¹, Katja Komossa, Werner Kissling

¹Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Möhlstr. 26, München, Germany, 81675.

The Cochrane Database of Systematic Reviews

|December 15, 2010

Summary

Second-generation antipsychotics like quetiapine show efficacy for generalized anxiety disorder but have significant side effects. Further research is needed for other anxiety disorders and antipsychotics.

Related Experiment Videos

Area of Science:

Pharmacology
Psychiatry
Clinical Trials

Background:

Anxiety disorders affect 17% of the population and often show resistance to existing treatments.
Second-generation antipsychotics are being explored as novel pharmacological options for anxiety disorders.
High rates of treatment resistance necessitate investigation into alternative therapeutic strategies.

Purpose of the Study:

To assess the effectiveness and safety of second-generation antipsychotics for anxiety disorders.
To evaluate these drugs as standalone treatments or in combination with other therapies.
To synthesize evidence from randomized controlled trials on antipsychotic use in anxiety.

Main Methods:

Systematic review of randomized controlled trials (RCTs) sourced from Cochrane registers and ClinicalTrials.gov.
Inclusion criteria encompassed RCTs comparing second-generation antipsychotics against placebo, benzodiazepines, pregabalin, or antidepressants.
Participants diagnosed with generalized anxiety disorder, panic disorder, or specific phobias were included.

Main Results:

Eleven RCTs involving 4144 participants evaluated olanzapine, quetiapine, and risperidone.
Quetiapine demonstrated significant efficacy over placebo for generalized anxiety disorder but was associated with increased adverse events, weight gain, sedation, and extrapyramidal symptoms.
No significant efficacy differences were found between quetiapine and antidepressants, though quetiapine had more adverse events. Olanzapine and risperidone showed no significant treatment effects in limited studies.

Conclusions:

Limited data exist for olanzapine and risperidone, precluding definitive conclusions.
Quetiapine monotherapy appears effective for generalized anxiety disorder symptoms, potentially comparable to antidepressants.
The benefits of quetiapine for generalized anxiety disorder must be balanced against its adverse tolerability profile.